- Home
- RAPT vs INVA Comparison
RAPT vs INVA Comparison
Compare RAPT & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RAPT | INVA |
|---|---|---|
| Founded | 2015 | 1996 |
| Country | United States | United States |
| Employees | 60 | 127 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2019 | 2000 |
Fundamental Metrics
Financial Performance| Metric | RAPT | INVA |
|---|---|---|
| Price | $58.00 | $22.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $56.22 | $36.50 |
| AVG Volume (30 Days) | ★ 4.1M | 804.5K |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 816.67 |
| EPS | N/A | ★ 3.30 |
| Revenue | N/A | ★ $217,217,000.00 |
| Revenue This Year | N/A | $7.22 |
| Revenue Next Year | N/A | $8.03 |
| P/E Ratio | ★ N/A | $6.95 |
| Revenue Growth | N/A | ★ 62.63 |
| 52 Week Low | $0.71 | $16.52 |
| 52 Week High | $57.99 | $25.15 |
Technical Indicators
Market Signals| Indicator | RAPT | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 78.59 | 58.42 |
| Support Level | $32.00 | $18.42 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.09 | 0.85 |
| MACD | -0.79 | -0.06 |
| Stochastic Oscillator | 95.31 | 37.83 |
Price Performance
Historical ComparisonAbout RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.